Daiwa Securities Group’s Harmony Biosciences HRMY Stock Holding History

Daiwa Securities Group’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-189	Closed	-$7K	–	1292
2025 Q4	$7K	Hold	189	–	–	﹤0.01%	1209
2025 Q3	$5K	Hold	189	–	–	﹤0.01%	1202
2025 Q2	$6K	Hold	189	–	–	﹤0.01%	1147
2025 Q1	$6K	Hold	189	–	–	﹤0.01%	1122
2024 Q4	$7K	Hold	189	–	–	﹤0.01%	1145
2024 Q3	$8K	Hold	189	–	–	﹤0.01%	1142
2024 Q2	$6K	Sell	189 -50	-21%	-$1.5K	﹤0.01%	1188
2024 Q1	$8K	Hold	239	–	–	﹤0.01%	1177
2023 Q4	$8K	Hold	239	–	–	﹤0.01%	1180
2023 Q3	$8K	Hold	239	–	–	﹤0.01%	1135
2023 Q2	$8K	Hold	239	–	–	﹤0.01%	1148
2023 Q1	$8K	Hold	239	–	–	﹤0.01%	1121
2022 Q4	$13K	Buy	239 +19	+9%	+$1.04K	﹤0.01%	1100
2022 Q3	$10K	Hold	220	–	–	﹤0.01%	1125
2022 Q2	$11K	Buy	220 +49	+29%	+$2.21K	﹤0.01%	1138
2022 Q1	$8K	Hold	171	–	–	﹤0.01%	1148
2021 Q4	$7K	Buy	+171	New	+$6.82K	﹤0.01%	1168

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Daiwa Securities Group's HRMY Position: Q1 2026 in Review

Daiwa Securities Group sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 189 shares — an estimated $7K sold.

Daiwa Securities Group first reported a position in HRMY in Q4 2021 and held it in 17 quarters. The position peaked at $13K in Q4 2022. 311 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

Daiwa Securities Group reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
Daiwa Securities Group sold 189 Harmony Biosciences shares in Q1 2026, an estimated $7K.
Daiwa Securities Group first reported a position in Harmony Biosciences in Q4 2021 and held it in 17 quarters.
Daiwa Securities Group's Harmony Biosciences position peaked at $13K in Q4 2022.
311 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.